XML 41 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT REPORTING
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The CODM for the Company is the Chief Executive Officer. The Company does not aggregate its operating segments for reporting purposes, and therefore, the reportable segments are the same as its operating segments.
Following the acquisition of Alimera and during the fourth quarter of 2024, the Company reorganized the segment information that is regularly provided to the chief operating decision maker which caused the identification of significant segment expenses to change. Therefore, the Company recasted prior period segment information to conform to the current-period presentation in accordance with the segment guidance at ASC 280-10-50-34.
The Company is now organized into two operating segments as follows:
•Rare Disease and Brands – Consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing and marketing of proprietary branded pharmaceutical products, with a strategic focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, and from September 16, 2024, through December 31, 2024, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of approximately 16 brand products that are principally sold in highly genericized markets.
•Generics and Other – Consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and other. As of December 31, 2024, this reporting segment was comprised of over 100 product families.
The CODM evaluates the performance of the Company as two operating segments based on revenues and Operating income (loss), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses, and transaction and integration expenses related to the acquisition of Alimera and other acquisitions.
The Company does not manage assets of the Company by operating segment and the CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.
Financial information by reportable segment is as follows:
Year Ended December 31, 2024
Generics and OtherRare Disease and BrandsCorporate and Unallocated Total
Net Revenues $320,034$294,342$— $614,376 
Cost of sales (excluding depreciation and amortization) (168,371)(81,839)— (250,210)
Research and Development (30,519)(14,062)— (44,581)
Selling, general, and administrative(5,120)(125,972)(118,544)(249,636)
Depreciation and amortization— — (67,731)(67,731)
Fair value adjustment — — 619 619 
Gain on sale of building— — 5,347 5,347 
Intangible asset impairment charge — — (7,600)(7,600)
Operating Income (Loss)$116,024$72,469$(187,909)$584 
Unrealized gain on investment in equity securities $—$—$6,307 6,307 
Interest expense, net — — (17,602)(17,602)
Other expense, net — — (4,033)(4,033)
Loss on extinguishment of debt— — (7,468)(7,468)
Income (Loss) Before Expense (Benefit) for Income Taxes $116,024$72,469$(210,705)$(22,212)
Year Ended December 31, 2023
Generics and OtherRare Disease and BrandsCorporate and UnallocatedTotal
Net Revenues$289,314$197,502$— $486,816 
Cost of sales (excluding depreciation and amortization)(152,739)(28,774)— (181,513)
Research and Development(28,197)(6,089)— (34,286)
Selling, general, and administrative(2,451)(73,466)(85,780)(161,697)
Depreciation and amortization— — (59,791)(59,791)
Fair value adjustment— — (1,426)(1,426)
Restructuring activities— — (1,132)(1,132)
Operating Income (Loss)$105,927$89,173$(148,129)$46,971 
Interest expense, net— — (26,940)(26,940)
Other expense, net— — (159)(159)
Income (Loss) Before Expense for Income Taxes$105,927$89,173$(175,228)$19,872 
Year Ended December 31, 2022
Generics and OtherRare Disease and BrandsCorporate and UnallocatedTotal
Net Revenues$235,237$81,148$— $316,385 
Cost of sales (excluding depreciation and amortization)(125,835)(12,950)— (138,785)
Research and Development(19,964)(2,354)— (22,318)
Selling, general, and administrative(3,963)(55,306)(64,775)(124,044)
Depreciation and amortization— — (56,972)(56,972)
Fair value adjustment— — (3,758)(3,758)
Restructuring activities— — (5,679)(5,679)
Intangible asset impairment charge ——(112)(112)
Operating Income (Loss)$85,475$10,538$(131,296)$(35,283)
Interest expense, net— — (28,052)(28,052)
Other income, net— — 670 670 
Income (Loss) Before Benefit for Income Taxes$85,475$10,538$(158,678)$(62,665)
Geographic Information
The following depicts the Company's total revenue according to geographic location. The Company has ceased operations at the Oakville, Ontario, Canada location as of March 31, 2023. The revenue from the acquisition of Alimera is also included in the year ended December 31, 2024 in the table below. The majority of the assets of the Company are located in the United States. The Company's operations are also located in the United Kingdom, Ireland, India, and Portugal.
The following table depicts the Company’s revenue by geographic operations during the following periods:
(in thousands)Years Ended December 31,
Location of Operations202420232022
United States$604,989$486,251$312,427
International9,3875653,958
Total Revenue$614,376$486,816$316,385
The following table depicts the Company’s property, plant and equipment, net according to geographic location, which excludes the land and building at the Company’s Canada facility, which was classified as held for sale as of December 31, 2023. These assets had a carrying value of approximately $8.0 million. The land and building at the Canada facility was sold on March 28, 2024, refer to Note 4 “Restructuring Canada Operations” to the notes to consolidated financial statements.
(in thousands)December 31, 2024December 31, 2023
United States$54,730$43,163
International2,1331,430
Total property and equipment, net$56,863$44,593